Under his leadership, BluMaiden has established drug discovery partnerships and collaborations, including with Cedars-Sinai Medical Centre, Los Angeles, and became an AWS Qualified Software Partner, delivering a scaled, validated platform for AI-augmented small molecule therapeutics discovery. He assembled the company's founding team, board of directors, and distinguished scientific advisory board – including Dr. Dermot McGovern, Cedars-Sinai and Co-Founder of Prometheus Biosciences; Dr. Terry Kelly, former Head of Chemistry at Boehringer Ingelheim; and Dr. Damian O’Connell, former SVP Drug Discovery at Bayer/Pfizer and now CEO of Singapore’s national drug discovery platform, EDDC – while securing strategic partnerships and funding to drive the company's growth.
In January 2026, Dr. Keogh founded the Irish Life Science Network Singapore (ILSNS), launched at an Irish Chamber of Commerce event supported by Ireland's former Prime Minister. He secured the patronage of the Irish Embassy in Singapore, Enterprise Ireland, IDA Ireland, and the Chamber. The network connects the Irish life sciences diaspora and supporters across Singapore and Asia-Pacific, strengthening collaboration between Ireland and Singapore's life science ecosystems, and has built strong early momentum, having already hosted five events and grown to hundreds of members across Europe and Asia-Pacific.
Dr. Keogh is Adjunct Professor at Trinity College Dublin’s School of Medicine, Board Advisor to SUSA – an EU-funded Pan-European initiative under the Digital Europe Programme spanning 12 universities across 9 countries – and a member of the Scientific Advisory Board for A*STAR Singapore’s ASMP 2.0 Program. Prior to BluMaiden, he held venture capital roles as Entrepreneur-in-Residence, contributing to biotech spin-outs, and is a Johnson & Johnson Innovation JLABS alumnus.
Dr. Keogh holds a B.Sc. in Biotechnology and a Ph.D. in Molecular Microbiology, with 12 years of international research experience in glycobiology and microbial-host interactions, producing multiple peer-reviewed, interdisciplinary publications. His Bristol Myers Squibb-sponsored academic research developed novel glycoselective bioaffinity technologies, resulting in a successful university spin-out.
在他的领导下，BluMaiden 与多家机构建立了药物发现合作关系，其中包括美国洛杉矶 Cedars-Sinai Medical Center。公司还成为 AWS Qualified Software Partner，构建并交付了一个规模化、经过验证的人工智能增强型小分子治疗药物发现平台。Keogh 博士组建了公司的创始团队、董事会及由知名专家组成的科学顾问委员会。委员会成员包括：Cedars-Sinai 的 Dermot McGovern 博士（Prometheus Biosciences 联合创始人）、Boehringer Ingelheim 前化学部门负责人 Terry Kelly 博士，以及曾任 Bayer/Pfizer 药物发现高级副总裁、现任新加坡国家药物发现平台 Experimental Drug Development Centre（EDDC）首席执行官的 Damian O’Connell 博士。此外，他还成功获得多项战略合作与资金支持，推动公司持续发展。
2026 年 1 月，Keogh 博士创立 Irish Life Sciences Network Singapore（ILSNS）。该网络在 Irish Chamber of Commerce 举办的一场活动上正式启动，并获得爱尔兰前总理支持。他还为该网络争取到爱尔兰驻新加坡大使馆、Enterprise Ireland、IDA Ireland 以及 Irish Chamber of Commerce 的支持。ILSNS 致力于连接新加坡及亚太地区的爱尔兰生命科学专业人士、侨界人才与支持者，促进爱尔兰与新加坡生命科学生态系统之间的合作。该网络成立后迅速发展，目前已举办五场活动，成员规模达数百人，分布于欧洲及亚太地区。
Keogh 博士现任都柏林圣三一大学医学院兼职教授，同时担任 SUSA 董事会顾问。SUSA 是由欧盟 Digital Europe Programme 资助的泛欧洲项目，覆盖 9 个国家的 12 所大学。他亦是新加坡科技研究局（A*STAR）ASMP 2.0 项目科学顾问委员会成员。在创立 BluMaiden 之前，他曾以驻场企业家（Entrepreneur-in-Residence）身份从事风险投资相关工作，并参与推动多家生物科技衍生企业的成立。此外，他还是 Johnson & Johnson Innovation JLABS 的校友。
Keogh 博士拥有生物技术理学学士学位及分子微生物学博士学位，并在糖生物学和微生物—宿主相互作用领域拥有 12 年的国际科研经验，发表了多篇经过同行评审的跨学科论文。他在学术界开展的、由 Bristol Myers Squibb 资助的研究开发了创新型糖选择性生物亲和技术，并成功促成一家大学衍生企业的成立。